Survival outcomes from the CALGB 40603 study in triple-negative breast cancer

Dr Sikov talks to ecancertv at SABCS 2015 about survival outcomes from the CALGB 40603 study involving women with stage II-III triple-negative breast cancer (TNBC) who were treated with carboplatin, bevacizumab, or both in addition to standard…

from #ORL-AlexandrosSfakianakis via simeraentaxei on Inoreader http://ift.tt/1QJLDwj
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1NDTMhG
via IFTTT